Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 6/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973124 | 0.86 | CHRM4 (0.54) | CHRM4CHRM2ACACBKMT2A | |
| SCHEMBL29839965 | 0.86 | CHRM4 (0.60) | CHRM4CHRM2ACACBNR1H2NR1H3 | |
| SCHEMBL21847855 | 0.86 | CHRM4 (0.60) | CHRM4CHRM2ACACBNR1H2NR1H3 | |
| SCHEMBL28707732 | 0.85 | CHRM4 (0.59) | CHRM4CHRM2NTRK1PROKR1ACACB | |
| SCHEMBL31614778 | 0.84 | MGLL (0.44) | CHRM4CHRM2KMT2A | |
| Lithium Ion SCHEMBL31016567 | 0.83 | CHRM4 (0.57) | CHRM4CHRM2NTRK1PROKR1ACACB | |
| SCHEMBL21847675 | 0.81 | CHRM4 (0.57) | CHRM4CHRM2ACACBKMT2A | |
| SCHEMBL21847696 | 0.81 | CHRM4 (0.57) | CHRM4CHRM2ACACBKMT2A | |
| SCHEMBL29973458 | 0.81 | CHRM4 (0.57) | CHRM4CHRM2ACACBCHRM1 | |
| SCHEMBL31647857 | 0.81 | CHRM4 (0.49) | CHRM4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | CHRM4 4/4885CHRM2 3/4885NTRK1 1870/4885 |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | CHRM1, CHRM5, CHRM2 | CHRM4 4/4885CHRM2 3/4885NTRK1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.